Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record.

Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial

Open access
Burks, A. Wesley, Wood, Robert A., Jones, Stacie M., Sicherer, Scott H., Fleischer, David M., Scurlock, Amy M., Vickery, Brian P., Liu, Andrew H., Henning, Alice K., Lindblad, Robert, Dawson, Peter, Plaut, Marshall, Sampson, Hugh A. · 2015 · Journal of Allergy and Clinical Immunology

Abstract

Background We previously reported initial results of the first multi-center randomized, double blind, placebo controlled clinical trial of peanut sublingual immunotherapy (SLIT), observing a favorable safety profile associated with modest clinical and immunologic effects in the first year. Objective To provide long-term (3-year) clinical and immunologic outcomes for our peanut SLIT trial. Key endpoints: (1) percentage of responders at 2 years (could consume 5g of peanut powder or a 10-fold increase from baseline), 2) percentage reaching desensitization at 3 years, (3) percentage attaining sustained unresponsiveness after 3 years, (4) immunologic endpoints and (5) assessment of safety parameters. Methods Response to treatment was evaluated in 40 subjects aged 12-40 years by performing a 10g peanut powder oral food challenge (OFC) following 2 and 3 years of daily peanut SLIT therapy. At 3 years, SLIT was discontinued for 8 weeks followed by another 10g OFC, and an open feeding of peanut butter to assess sustained unresponsiveness. Results Approximately 98% of the 18,165 doses were tolerated without adverse reactions beyond the oropharynx, with no severe symptoms or uses of epinephrine. A high rate (>50%) discontinued therapy. By study end, 4/37 (10.8%) of SLIT treated participants were fully desensitized to 10g of peanut powder, and all 4 achieved sustained unresponsiveness. Responders at 2 years showed a significant decrease in peanut-specific basophil activation and skin prick test titration compared to non-responders. Conclusions Peanut SLIT induced a modest level of desensitization, decreased immunologic activity over 3 years in responders, and had an excellent long-term safety profile. However, most patients discontinued therapy by the end of year 3, and only 10.8% of subjects achieved sustained unresponsiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2014.12.1917

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Burks, A. W., Wood, R. A., Jones, S. M., Sicherer, S. H., Fleischer, D. M., Scurlock, A. M., Vickery, B. P., Liu, A. H., Henning, A. K., Lindblad, R., Dawson, P., Plaut, M., & Sampson, H. A.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2015-05
Volume
135
Issue
5
Pages
1240-1248.e3
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2040635028
Cited by
189
References
0
FWCI
23.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. https://app.cochat.ai/papers/10.1016/j.jaci.2014.12.1917
The paper
Burks, A. W., Wood, R. A., Jones, S. M., Sicherer, S. H., Fleischer, D. M., Scurlock, A. M., Vickery, B. P., Liu, A. H., Henning, A. K., Lindblad, R., Dawson, P., Plaut, M., & Sampson, H. A. (2015). Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2014.12.1917

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.